Filter posts

BIO Submits Comments on “Myriad” PTO Patent Guidance

On July 31st, BIO, alongside a group of international bioindustry trade associations submitted comments to …

Patently Biotech’s Top Articles of 2013

Intellectual property featured prominently in 2013’s public discourse. Gene patents, patent trolls, India’s anti-patent actions, …

Patent Docs Highlights the BIO IPDx Symposium

Patent Docs recently highlighted McDonnell Boehnen Hulbert & Berghoff’s (MBHB) panel at BIO’s IP and …

Myriad Supreme Court Decision: BIO’s Statement

Statement On U.S. Supreme Court Review Of Isolated DNA Patents Washington, D.C. (June 13, 2013) …

Gene Patents, Angelina Jolie, and Reality

By Dr. Hans Sauer, J.D., Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization  Angelina …

Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here

Bio IT World just published an article stating that the Myriad Supreme Court case will …

AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision

BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad …

USPTO Blogpost Brings Mayo Down to Earth

The United States Patent and Trademark Office Director David Kappos posted a blogpost called “Some …

The U.S. Government’s Position in ACLU v. Myriad Genetics

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, comments on  the Department of Justice’s brief …

Recent Developments in Patentability: Prometheus and Myriad

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at …